Yüklüyor......
Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS...
Kaydedildi:
| Yayımlandı: | Therap Adv Gastroenterol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5598815/ https://ncbi.nlm.nih.gov/pubmed/28932270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17726087 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|